All In MedTech

Device Trial Radar · NCT05621876

Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia

Evaluation of an IgG Deficiency Rapid Screening Test (RDT) With Human Capillary Samples: A Protocol to Generate RDT Performance Data in Primary Immunodeficiency Patients (PID)

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

May 15, 2024

Primary completion

Sep 1, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
PATHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Institut Pasteur de Tunis; Centre National de Greffe de Moelle Osseuse
First posted
Nov 18, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 6 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the usability and utility of the device, % agreement between the PID-RDT and the referent assay (serum/plasma), and % agreement between capillary blood and venous blood samples using the PID-RDT within confirmed PID patients prior to receipt of their monthly IV-Ig treatment.

Conditions

  • Primary Immunodeficiency Diseases

Interventions

  • IgG deficiency rapid screening testDevice

    We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluateusability among end users of the PID rapid screening tests using capillary blood samples obtained from PID patients, prior to receipt of IV-Ig treatment.Time frame: 3 month
  2. To evaluate % agreement between the PID RDT(using capillary blood)and the referent test (serum/plasma).Time frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Bone Marrow Transplant center

    Tunis, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.